Investigation of the effectiveness of mefenamic acid administration on the outcome of frozen-thawed embryo transfer in infertile women referred to Shariati Hospital, Tehran University of Medical Sciences in 2021

Investigation of the effectiveness of mefenamic acid administration on the outcome of frozen-thawed embryo transfer in infertile women

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240514061800N2

Enrollment

200

Registered

2024-07-04

Start date

2022-07-11

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility. Other obstetric conditions, not elsewhere classified

Interventions

Intervention 1: Intervention group: Patients in the intervention group are prescribed 250 mg mefenamic acid capsules manufactured by Elhawi Pharmaceutical Company one to two hours before embryo transf

Eligibility

Sex/Gender

Female

Age

18 Years to 42 Years

Inclusion criteria

Inclusion criteria: Age less than 42 years All patients who entered the cycle and have frozen embryos due to infertility caused by male factors, tubal factors, endometriosis, decreased ovarian reserve, PCO and unexplained.

Exclusion criteria

Exclusion criteria: Lack of consent to participate in the study Structural abnormalities of the uterus confirmed by imaging or hysteroscopy. Patients who are not allowed to get pregnant for any reason.

Design outcomes

Primary

Measure	Time frame
Increased serum B-HCG level. Timepoint: Two weeks after the intervention. Method of measurement: Biochemical tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAyda Najafian

Tehran University of Medical Sciences

aidanajafian@yahoo.com+98 21 8800 8810

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026